Celltrion’s Rituximab Biosimilar Is The First Greenlit By The FDA

Truxima (rituximab-abbs) becomes the first biosimilar to Rituxan approved by the US agency, although launch timing remains unclear; Celltrion also has novel infliximab subcutaneous formulation accepted for review by the EMA.

Traffic light
FDA gives Truxima the green light

The first biosimilar with non-Hodgkin’s lymphoma (NHL) indications, Celltrion’s Truxima (rituximab-abbs), has passed the US Food and Drug Administration (FDA) approval process, becoming also the first Rituxan (rituximab) biosimilar authorised in the US.

Launch plans for Truxima remain unclear, for now. While the Korean firm and commercialisation partner Teva earlier this year announced...

Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

More from Biosimilars

More from Products

  • For Generics, A Victory Lap – And A Warning – On Drug Shortages

    Avoiding disaster at the beginning of the pandemic and offering a pro-active supply chain blueprint should position the generics industry well for an onshoring debate in Congress, but a look back at March 2020 is a reminder that even small policy shifts can have a big impact.

  • GB-Free-Company-The Secret to Walking More: It’s Not Counting Steps

    We’ve all been told that walking 10,000 steps a day is the magic number for better health. But what if the real secret to walking more isn’t about counting steps at all? In this article, we explore how focusing on motivation, environment, and mindset can help you build a walking habit that lasts.

  • Biocon And Teva Sign Up To Biosimilars Forum

    Teva and Biocon Biologics have become the latest firms to sign up to the Biosimilars Forum industry association in the US.